Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)

Active, not recruiting

Phase 4 Results N/A

Summary of Purpose

The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 11 September 2006.

1 Dec 2004 18 Apr 2005 Unavailable 1 Sep 2007 1 Sep 2006 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double-Blind
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

Not available